VRDN-006 / Viridian Therap - LARVOL DELTA

VRDN-006 Showed IgG Reduction Proof-of-Concept in Healthy Volunteers. (FinancialContent) - "VRDN-006 showed IgG reductions in its ongoing phase 1 clinical trial consistent with the FcRn inhibitor class. VRDN-006 was sparing of albumin and LDL and was generally well-tolerated, with no dose-limiting toxicities or serious adverse events."

P1 data • Immunology

Viridian Therapeutics Highlights 2025 Corporate Priorities... (Businesswire) - "Viridian submitted an IND for VRDN-006 in December 2024 and, upon clearance, anticipates initiating a phase 1 clinical trial in healthy volunteers in early 2025...Viridian expects data from the phase 1 clinical trial in Q3 2025, including proof-of-concept IgG reductions in healthy volunteers."

New P1 trial • P1 data • Immunology